APA (7th ed.) Citation

A, O., F, M., F, R., S, P., F, K., A, H. E., . . . M, B. (2022). Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. Iranian journal of basic medical sciences, 25(3), 313. https://doi.org/10.22038/IJBMS.2022.62522.13834

Chicago Style (17th ed.) Citation

A, Oghalaie, et al. "Development and Characterization of Single Domain Monoclonal Antibody Against Programmed Cell Death Ligand-1; as a Cancer Inhibitor Candidate." Iranian Journal of Basic Medical Sciences 25, no. 3 (2022): 313. https://doi.org/10.22038/IJBMS.2022.62522.13834.

MLA (9th ed.) Citation

A, Oghalaie, et al. "Development and Characterization of Single Domain Monoclonal Antibody Against Programmed Cell Death Ligand-1; as a Cancer Inhibitor Candidate." Iranian Journal of Basic Medical Sciences, vol. 25, no. 3, 2022, p. 313, https://doi.org/10.22038/IJBMS.2022.62522.13834.